Objective: To study the protective effect of Buyanghuanwu Decoction on myocardial ischemia induced by isoproterenol in rats.
Methods: Buyanghuanwu Decoction was given in different dose and the rat model of myocardial ischemia was established by peritoneal injection of isoproterenol. The expression of CD40 in whole blood was detected by flow cytometry,and the expression of CD40L in myocardial tissues was detected by immunohistochemistry. The activities of lactate dehydrogenase (LDH), creatine kinase (CK) and aspartate aminotransferase (AST) in blood serum were detected by biochemistry detector.
Results: Compared with the model group, Buyanghuanwu Decoction in high and middle dose significantly inhibited the expression of CD40 in blood serum and CD40L in myocardial tissues (P < 0.01), and obviously decreased the activities of LDH, CK and AST in blood serum (P < 0.01).
Conclusion: Buyanghuanwu Decoction has a protective effect on myocardial ischemia induced by isoproterenol in rats, and it may be relevant to the decrease of the expression of CD40-CD40L and the activities of myocardial enzymes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
BuyangHuanwu Decoction alleviates Endothelial Cell Apoptosis and Coronary Microvascular Dysfunction via Regulation of the MAPKK4/p38 Signaling Axis.
Int J Med Sci
October 2024
Senior Department of Cardiology, The Sixth Medical Center of People's Liberation Army General Hospital, Beijing, China.
MAPKK4 has been implicated in the pathological mechanisms underlying myocardial and vascular injury, specifically influencing endothelial cell damage and programmed cell death via subcellular pathways. Nevertheless, the regulatory role of MAPKK4 in coronary microvascular injury following myocardial infarction remains unconfirmed, and the exploration of targeted mitochondrial protective therapeutic agents remains unaddressed. In light of this gap, we established a MAPKK4 gene-modified mouse model of ischemia-reperfusion injury and employed Buyang Huanwu decoction (BYHW), a traditional cardiovascular therapeutic formula, to assess its efficacy in treating coronary microvascular injury post-ischemia-reperfusion.
View Article and Find Full Text PDFExploration of the Mechanisms of Bu-Yang-Huan-Wu Decoction in the Treatment of Diabetic Peripheral Neuropathy by Integrating of Serum Pharmacochemistry and Network Pharmacology.
Chem Biodivers
September 2024
Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM and Engineering & Technology Research Center for Chinese Materia Medica Quality of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Diabetic peripheral neuropathy (DPN) is a significant and frequent complication of diabetes. Bu-Yang-Huan-Wu Decoction (BHD) is a classic traditional Chinese herbal prescription that is commonly used in modern clinical practice for the effective treatment of DPN, but the underlying mechanism is not yet clearly defined. The chemical constituents of BHD were characterized by UPLC-Q-Orbitrap HR MS/MS, and a total of 101 chemical components were identified, including 30 components absorbed into blood.
View Article and Find Full Text PDFMeta-analysis was used to analyze the efficacy of conventional western medicine plus Buyanghuanwu Decoction in the treatment of convalescent patients with stroke, and to observe its influence on the neurological function and condition of patients. According to the research direction and set keywords, the research literature was retrieved from Wanfang Medical Science, CNKI, VIP, PubMed and other domestic and foreign literature databases. A total of 13 articles with 1023 patients were included in this meta-analysis, with a large sample size.
View Article and Find Full Text PDFElucidating the Mechanism of Buyanghuanwu Decoction Acting on Pulmonary Fibrosis Based on Network Pharmacology and Animal Studies.
Comb Chem High Throughput Screen
June 2024
Department of Clinical , Xiangtan Central Hospital, Xiangtan, Hunan, 411100, China.
Background And Objective: Buyanghuanwu Decoction (BYHWD) is a clinically proven prescription effective in treating pulmonary fibrosis (PF), but the molecular mechanism underlying its action remains unclear. The network pharmacology analysis was performed to elucidate the acting substances and related pathways of BYHWD in treating bleomycin (BLM) induced PF mouse.
Methods: First, the pharmacologically active components and corresponding targets in BYHWD were identified through the TCMSP database and literature review.
QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway.
J Ethnopharmacol
October 2023
Basic Medical College, Guizhou University of Traditional Chinese Medicine, 550025, Guiyang, Guizhou, China. Electronic address:
Ethnopharmacological Relevance: QiShenYiQi pill (QSYQ), a Chinese compound medicine, originate from BuYangHuanWu decoction in the Qing dynasty, and has been used to treat ischemic cardiovascular diseases for more than two hundred years in China. Multi-central randomized double-blind controlled studies have proved that QSYQ has similar efficacy as enteric coated aspirin in the secondary prevention of myocardial infarction.
Aim Of Study: The aim of study was to explore the effect of QSYQ on reverse cholesterol transport (RCT) pathway during atherosclerosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!